These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 236372)

  • 41. Alkylating esters. X. The reaction of some aziridine alkylating agents with methionine and S-methyl cysteine.
    Jones AR; Capps PA
    Chem Biol Interact; 1977 Feb; 16(2):181-9. PubMed ID: 849623
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.
    Juma FD; Rogers HJ; Trounce JR
    Br J Clin Pharmacol; 1979 Sep; 8(3):209-17. PubMed ID: 497087
    [No Abstract]   [Full Text] [Related]  

  • 43. Pharmacokinetics of methylprednisolone, methylprednisolone sodium succinate, and methylprednisolone acetate in dogs.
    Toutain PL; Koritz GD; Fayolle PM; Alvinerie M
    J Pharm Sci; 1986 Mar; 75(3):251-5. PubMed ID: 3517294
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The clinical pharmacology of a hepatoma-specific alkylating agent.
    Curt CA; Cannors TA; Murray-Lyon IM; Tattersall MH
    Biochem Pharmacol; 1977 Sep; 26(18):1715-8. PubMed ID: 197970
    [No Abstract]   [Full Text] [Related]  

  • 45. [Kinetics of the N,N-dimethyl-2-phenylaziridinium reaction with a muscarinic cholinoreceptor and acetylcholinesterases].
    Palumaa PIa; Kiaémbre TKh; Iarv IaL
    Bioorg Khim; 1983 Oct; 9(10):1348-56. PubMed ID: 6679758
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I and pharmacokinetic study of trans-N3P3Az2(NHMe)4.
    Mulder NH; Meijers WH; van der Meulen JD; Sleijfer DT; Uges DR; de Vries EG; Postmus PE; van de Grampel JC; Willemse PH
    Cancer Treat Rep; 1987 Feb; 71(2):155-9. PubMed ID: 3026625
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of ceftazidime after intravenous, intramuscular and subcutaneous administration to dogs.
    Monfrinotti A; Ambros L; Prados AP; Kreil V; Rebuelto M
    J Vet Pharmacol Ther; 2010 Apr; 33(2):204-7. PubMed ID: 20444047
    [No Abstract]   [Full Text] [Related]  

  • 48. Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone.
    Zimm S; Collins JM; Curt GA; O'Neill D; Poplack DG
    Cancer Res; 1984 Apr; 44(4):1698-701. PubMed ID: 6704975
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pharmacological study on kasugamycin].
    Matsuzaki A; Yoshida A; Onodera K; Sekino M; Tado N; Asano M
    Jpn J Antibiot; 1968 Aug; 21(4):206-20. PubMed ID: 5304357
    [No Abstract]   [Full Text] [Related]  

  • 50. [Effect of the alkylating agent, dipin, on induced hepatocyte proliferation. II. An increase in the DNA synthesis period].
    Uryvaeva IV; Faktor VM; Brodskiĭ VIa
    Tsitologiia; 1979 Jun; 21(6):678-85. PubMed ID: 462544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of buffer composition on water stability of alkylating agents. The example of N-ethyl-N-nitrosourea.
    Tosato ML; Terlizzese M; Dogliotti E
    Mutat Res; 1987 Aug; 179(2):123-33. PubMed ID: 3614242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Determination of diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone in plasma by solid-phase extraction and high-performance liquid chromatography.
    Betteridge RF; Bosanquet AG; Hunt P; Gilby ED
    J Chromatogr; 1988 Nov; 432():352-7. PubMed ID: 3220904
    [No Abstract]   [Full Text] [Related]  

  • 53. Pharmacokinetic aspects of drug metabolism.
    Gibaldi M
    Ann N Y Acad Sci; 1971 Jul; 179():19-31. PubMed ID: 4936775
    [No Abstract]   [Full Text] [Related]  

  • 54. Biochemical activation of AZQ [3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone] to its free radical species.
    Gutierrez PL; Friedman RD; Bachur NR
    Cancer Treat Rep; 1982 Feb; 66(2):339-42. PubMed ID: 6275990
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effect of the alkylating agent dipin on the induced proliferation of hepatocytes. I. The kinetics of the cell population].
    Faktor VM; Uryvaeva IV; Sokolova AS; Chernov VA; Brodskiĭ VIa
    Tsitologiia; 1979 May; 21(5):541-7. PubMed ID: 462539
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Studies on aziridine derivatives. III. Synthesis and immunopharmacological activity of aziridine derivatives of propionic acid.
    Kowalczyk-Bronisz SH; Pomorski J; Zabska R
    Arch Immunol Ther Exp (Warsz); 1988; 36(3):249-67. PubMed ID: 3266917
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemical mechanism of the radiation potentiating effects of 2,2-dimethylaziridine-type antitumor agents.
    Bardos TJ; Dunn JA; Perlman ME
    Int J Radiat Oncol Biol Phys; 1979 Sep; 5(9):1653-6. PubMed ID: 536272
    [No Abstract]   [Full Text] [Related]  

  • 58. [Pharmacokinetics of arbekacin in dogs. I. Serum concentration and urinary excretion].
    Tomono N; Sannomiya F; Nakayoshi T; Shinkai S; Fujita M
    Jpn J Antibiot; 1987 Feb; 40(2):365-75. PubMed ID: 3599385
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of three aziridine alkylating compounds on the gross development of chicken embryos.
    Younger RL
    Toxicol Appl Pharmacol; 1973 Mar; 24(3):423-33. PubMed ID: 4122266
    [No Abstract]   [Full Text] [Related]  

  • 60. Bis(1-aziridinyl)morpholinophosphine sulphide.
    IARC Monogr Eval Carcinog Risk Chem Man; 1975; 9():55-60. PubMed ID: 825437
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.